Table 1. Clinical details of patients with primary lacrimal sac lymphoma.
| Patient | Age/sex | Eye | Anatomy | Pathologic diagnosis | Symptoms at first visit | Pathogen | Tumor marker positivity | History | Surgery | Chemotherapy | Follow-up |
| 1 | 37/F | R | Lacrimal sac, nasolacrimal duct | DLBCL | Epiphora, mass of lacrimal sac | HBsAg | Hcy | Hepatitis B | Mass resection and DCR | 4 cycle R-CHOP | Survival: 41 mo, no epiphora |
| 2 | 88/M | R | Canaliculus, larimal sac, nasolarimal duct | DLBCL | Epiphora, mass of medial canthal | Hcy B2M | Mass resection and DCR | none (refusal) | Survival: 39 mo, no epiphora | ||
| 3 | 49/M | L | Canaliculus, larimal sac, nasolarimal duct | DLBCL | Epiphora, mass | Not determined | Hcy | Mass resection and DCR | 6 cycle R-CHOP | Survival: 37 mo, no epiphora | |
| 4 | 47/F | R | Larimal sac, nasolarimal duct | DLBCL | Epiphora, mass | Not determined | Hcy | Mass resection and DCR | 6 cycle R-CHOP | Survival: 34 mo, no epiphora | |
| 5 | 43/F | R | Larimal sac | MALT lymphoma | Epiphora, mass of medial canthal, mucopurulent discharge | Hcy B2M | Intubationa | Mass resection | 4 cycle R-CHOP | Survival: 33 mo, epiphora | |
| 6 | 57/M | R | Larimal sac, nasolarimal duct | DLBCL | Epiphora, mass | Hcy B2M | Mass resection | 6 cycle R-CHOP | Survival: 32 mo, epiphora | ||
| 7 | 55/M | R | Canaliculus, larimal sac | MALT lymphoma | Epiphora, mass of medial canthal | ND | Hcy B2M | Mass resection and DCR | 4 cycle R-CHOP | Survival: 30 mo, no epiphora | |
| 8 | 29/F | L | Canaliculus, larimal sac, nasolarimal duct | NK/T-cell lymphoma, nasal type | Epiphora, red and swelling of medial canthal | Epstein-Barr virus | Hcy B2M LDH | No initial fever; fever developed | Mass resection | 2 cycle R-CHOP | Death: 4 mo, epiphora |
| 9 | 58/M | R | Larimal sac | MALT lymphoma | Epiphora, mass | Not determined | Hcy | Mass resection | None | Survival: 26 mo, epiphora | |
| 10 | 69/F | R | Larimal sac, nasolarimal duct | DLBCL | Epiphora, mass | Not determined | Hcy B2M | Mass resection | 6 cycle R-CHOP | Survival: 25 mo, epiphora | |
| 11 | 71/M | L | Canaliculus, larimal sac | MALT lymphoma | Epiphora, mass | Not determined | Hcy B2M | Mass resection | None | Survival: 21 mo, epiphora | |
| 12 | 60/F | R | Canaliculus, larimal sac, nasolarimal duct | DLBCL | Epiphora, mass of medial canthal, mucopurulent discharge | Mass resection and DCR | 4 cycle R-CHOP | Survival: 21 mo, no epiphora | |||
| 13 | 62/F | L | Canaliculus, larimal sac | MALT lymphoma | Epiphora | Not determined | Hcy | Mass resection | 4 cycle R-CHOP | Survival: 19 mo, epiphora | |
| 14 | 73/F | L | Larimal sac, nasolarimal duct | DLBCL | Epiphora, mass | Not determined | Hcy B2M | Mass resection and DCR | 4 cycle R-CHOP | Survival: 19 mo, no epiphora | |
| 15 | 50/M | L | Canaliculus, larimal sac, nasolarimal duct | NK/T-cell lymphoma, nasal type | Epiphora, discharge, redness and swelling of medial canthal | Epstein-Barr virus | Hcy B2M LDH | No initial fever; fever developed | Mass resection | 3 cycle R-CHOP | Death: 6 mo, epiphora |
B2M: β2 microglobulin; DCR: dacryocystorhinostomy; DLBCL: Diffuse large B-cell lymphoma; F: Female; Hcy: Homocysteine; L: Left; LDH: Lactate dehydrogenase; M: Male; MALT lymphoma: Mucosa-associated lymphoid tissue lymphoma; NK/T-cell lymphoma, nasal type: Natural killer/T-cell lymphoma, nasal type; R: Right; R-CHOP: Rituximab, cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone. aPatient-5 received intubation for epiphora, which did not improve after the surgery, followed by the growth of a medial canthus mass.
n=15